

PSB 118 Data Dependent Constant Neutral Loss Scan Function for Identification of Biotransformations using Finnigan Ion Trap Mass Spectrometers

Page 1 of 2

Determination of the metabolic fate of drugs is an essential and important part of the drug development process. *In vitro* biotransformation studies are commonly performed in the early drug discovery to determine metabolic pathways and to generate Phase I and Phase II metabolites for further characterization. In Phase I reactions, the parent compounds undergo hydrolysis, oxidation and reduction. Phase II reactions involve glucuronidation, sulfation, methylation, acetylation, glutathione and amino acid conjugation. Each of these transformations shows a characteristic mass shift with respect to the molecular ion of the parent compound as listed in Table 1.

Biotransformation	Change in mass
Oxidation	M+16
N-hydroxylation	M+16
Reduction	M+2
Methylation	M+14
Acetylation	M+42
Sulfation	M+80, M+96
Glucuronidation	M+176, M+192
Taurine Conjugation	M+107
Cys Conjugation	M+121, M+119
GSH Conjugation	M+307, M+305

Table 1. Mass shifts for some common biotransformations

The wide variety of potential metabolites and resulting complex mixtures make their identification a challenging and labor-intensive task. The Data Dependent™ constant neutral loss (DDCNL) scan function that is available on all Finnigan™ Ion Trap Mass spectrometers significantly expedites identification of these metabolites.

A flow chart of the scan events for a DDCNL experiment is shown in Figure 1. The DDCNL experiment performs an MS scan followed by an MS/MS scan of the most intense peak to look for a user-defined neutral loss. If the MS/MS scan produces a fragment with the targeted neutral loss, an MS³ scan of the product ion is initiated. However, if the fragments in the MS/MS scan do not correspond to the targeted neutral loss, the software moves on to the next most intense peak in the MS scan and performs another MS/MS experiment.




Figure 1. Flow chart for DDCNL scan events

This sequence is repeated for a preset number of ions in the MS scan. The triggering of the MS³ scan event then points to the ions that exhibit a particular structural motif. The benefit of DDCNL is that by performing MS³ scans only on those compounds that show the desired neutral loss, the mass spectrometer can rapidly scan for low intensity ions.

Data Dependent Constant Neutral Loss Scan Function for Identification of Biotransformations using Finnigan Ion Trap Mass Spectrometers

Page 2 of 2

An application of DDCNL scanning to identify *in vitro* metabolites of glyburide is illustrated in Figure 2. This experiment was performed with a user-defined neutral loss of 125. By scanning the chromatogram in real time for a constant neutral loss of 125, the DDCNL scan function triggers an MS³ scan for a metabolite at *m/z* 510. Metabolite ID and Mass Frontier™ were subsequently used to identify the site of hydroxylation in this metabolite.

DDCNL is a technique that increases selectivity for identification of metabolic modifications. It also simplifies the analysis of complex mixtures in biological matrices, and enables characterization of low abundance species. This scan technique can be used for the analysis of biotransformations, and can also be applied to the analysis of compound transformations, such as degradation or by-product analyses.




Figure 2: LC-MS/MS analysis with Data Dependent Constant Neutral Loss-triggered MS³ for the analysis of *in vitro* metabolites of glyburide generated from incubation with rat liver microsomes.

Mass Frontier is a trademark of HighChem, Ltd. All other trademarks are the property of Thermo Electron Corporation and its subsidiaries.